Sir,
We thank Dr Chhablani1 for his interest in our article2; we evaluated diffuse diabetic macular oedema and obtained good functional and anatomic results during a follow-up of 12 months after treatment with intravitreal bevacizumab, when compared with the combination of intravitreal triamcinolone and laser photocoagulation. We agree that intravitreal bevacizumab lacks in large randomized controlled trials and could be used in case of gross macular oedema in order to reduce macular thickening, followed by laser photocoagulation. The latter remains indeed the gold standard for diabetic macular oedema.
References
Chhablani JK . Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema. Eye 2011; 25 (2): 254.
Forte R, Cennamo GL, Finelli M, Farese E, D'Amico G, Nicoletti G et al. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Eye 2010; 24 (8): 1325–1330.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Forte, R., Cennamo, G., Finelli, M. et al. Reply to Chhablani. Eye 25, 254 (2011). https://doi.org/10.1038/eye.2010.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2010.183
